Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.

Martin Reck,Tudor-Eliade Ciuleanu,Manuel Cobo-Dols,Michael Schenker,Bogdan Żurawski,Juliana Menezes,Eduardo Richardet,Jaafar Bennouna,Enriqueta Felip,Oscar Juan-Vidal,Aurella Alexandru,Hiroshi Sakai,Arnaud Scherpereel,Shun Lu,Thomas John,David P. Carbone,Stephanie Meadows-Shropshire,Jinchun Yan,Luis Paz-Ares

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.

2020

Martin Reck
Tudor-Eliade Ciuleanu
Manuel Cobo-Dols
Michael Schenker
Bogdan Żurawski
Juliana Menezes
Eduardo Richardet
Jaafar Bennouna
Enriqueta Felip
Oscar Juan-Vidal
Aurella Alexandru
Hiroshi Sakai
Arnaud Scherpereel
Shun Lu
Thomas John
David P. Carbone
Stephanie Meadows-Shropshire
Jinchun Yan
Luis Paz-Ares

9501Background: NIVO + IPI was shown to improve overall survival (OS) and durability of response vs chemo in 1L advanced NSCLC in CheckMate 227 Part 1, regardless of PD-L1 expression. We hypothesiz...

Keywords:

Oncology
Recurrent Non-Small Cell Lung Cancer
Ipilimumab
Chemotherapy
first line
Internal medicine
Checkmate
Pathology
Nivolumab
stage iv
Medicine
overall survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations